Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma

Completed · Phase 1/Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.

Key facts

Study ID

NCT00116441

Run by

Cell Genesys

People needed

22

Starts

2000-10-01

Expected to finish

2004-10-01

Last updated by the study team

2007-12-24

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• De novo multiple myeloma
• ECOG 0-2
• No serious co-morbid illnesses and adequate organ function
• > 4 weeks from systemic steroids

You may not qualify if…

• No existing secondary malignancies and no history of secondary malignancies in the past 5 years
• No active autoimmune disease

Where it is running

• Johns Hopkins University — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.